Our Commitment

Our Commitment

Committed to innovation

Patients are at the center of everything we do at Akcea, and we know you are counting on us.

There is a significant need for new therapies targeting the proteins associated with serious and rare diseases. That’s why we’re on a mission to transform the treatment of these unaddressed or under-addressed complex diseases.

Committed to advocacy

Beyond advancing our novel, investigational medicines for serious and rare disorders, we are also committed to supporting the broader needs of the associated communities. From developing educational resources to connecting patients to others who may share their experience, we are driven to be a partner in channeling patient voices into purposeful actions.

At Akcea, we take great care in how we partner with patient and other healthcare organizations around these common goals. We respect patient organizations as independent, sustainable, and self-led communities.

If you are an advocacy organization interested in partnering with Akcea to better serve patients living with the diseases of ATTR amyloidosis, familial chylomicronemia syndrome, familial partial lipodystrophy or a cardiometabolic lipid disorder such as high Lp(a), or if you are a patient, family member or caregiver that would like to share your story with us or participate in our patient advocacy efforts, we look forward to hearing from you and getting to know you. Contact us at patientadvocacy@akceatx.com.


Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. For continued news and information about Akcea Therapeutics, please visit ionispharma.com. You are being redirected, please wait. If you have not been redirected in 30 seconds, please click the button below.

Go to ionispharma.com